journal article·2024-06-19

Reprogrammed IDO-Induced Immunosuppressive Microenvironment Synergizes with Immunogenic Magnetothermodynamics for Improved Cancer Therapy

Xun Wang, Bin Yan, Hugang Li, Jianlan Yuan, Jingyi Guo, Siyao Wang, Penggao Dai, Xiaoli Liu

ACS Applied Materials & Interfaces· Volume 16· Issue 24
Publisher page

Abstract

Indoleamine 2,3-dioxygenase (IDO), highly expressed in hepatocellular carcinoma (HCC), plays a pivotal role in creating an immune-suppressive tumor microenvironment. Inhibiting IDO activity has emerged as a promising immunotherapeutic strategy; however, the delivery of IDO inhibitors to the tumor site is constrained, limiting their therapeutic efficacy. In this study, we developed a magnetic vortex nanodelivery system for the targeted delivery of the IDO inhibitor NLG919, integrated with magnetic hyperthermia therapy to reverse the immune-suppressive microenvironment of liver cancer and inhibit tumor growth. This system comprises thermoresponsive polyethylenimine-coated ferrimagnetic vortex-domain iron oxide nanorings (PI-FVIOs) loaded with NLG919 (NLG919/PI-FVIOs). Under thermal effects, NLG919 can be precisely released from the delivery system, counteracting IDO-mediated immune suppression and synergizing with NLG919/PI-FVIOs-mediated magnetothermodynamic (MTD) therapy-induced immunogenic cell death (ICD), resulting in effective HCC suppression. In vivo studies demonstrate that this combination therapy significantly inhibits tumor growth and metastasis by enhancing the accumulation of cytotoxic T lymphocytes and suppressing regulatory T cells within the tumor. Overall, our findings reveal that NLG919/PI-FVIOs can induce a potent antitumor immune response by disrupting the IDO pathway and activating the ICD, offering a promising therapeutic avenue for HCC treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Tryptophan and brain disorders · Immune cells in cancer · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology of Shaanxi Province, Northwest University, Xi’an, Shaanxi 710069, China

Shaanxi Lifegen Co., Ltd., Xi’an, Shaanxi 712000, China

National Engineering Research Center for Miniaturized Detection Systems, College of Life Science, Northwest University, Xi’an, Shaanxi 710069, China

National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine; Shaanxi Province Center for Regenerative Medicine and Surgery Engineering Research; Shaanxi Provincial Key Laboratory of Magnetic Medicine, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China

Institute of Regenerative and Reconstructive Medicine, Med-X Institute, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710049, China

Funding

Natural Science Foundation of Shaanxi Province · Key Research and Development Projects of Shaanxi Province · Shaanxi Province Youth Science and Technology New Star

References (42)

Show source-provided references
1. 10.3322/caac.2176310.3322/caac.21763 ↗
2. 10.3322/caac.2173110.3322/caac.21731 ↗
3. 10.3322/caac.2166010.3322/caac.21660 ↗
4. 10.1038/s41572-020-00240-310.1038/s41572-020-00240-3 ↗
5. 10.1056/NEJMra171326310.1056/NEJMra1713263 ↗
6. 10.1016/j.tips.2017.10.00910.1016/j.tips.2017.10.009 ↗
7. 10.1016/j.molcel.2020.05.03410.1016/j.molcel.2020.05.034 ↗
8. 10.1038/s41422-020-0337-210.1038/s41422-020-0337-2 ↗
9. 10.1038/s41571-018-0073-410.1038/s41571-018-0073-4 ↗
10. 10.1126/sciimmunol.aau658410.1126/sciimmunol.aau6584 ↗
11. 10.1016/j.ccell.2020.07.00410.1016/j.ccell.2020.07.004 ↗
12. 10.1038/s41577-019-0218-410.1038/s41577-019-0218-4 ↗
13. 10.1158/2326-6066.CIR-19-004010.1158/2326-6066.CIR-19-0040 ↗
14. 10.3390/cancers1320518010.3390/cancers13205180 ↗
15. 10.1038/nm93410.1038/nm934 ↗
16. 10.1007/s00432-008-0395-110.1007/s00432-008-0395-1 ↗
17. 10.1172/JCI3117810.1172/JCI31178 ↗
18. 10.1038/nrc263910.1038/nrc2639 ↗
19. 10.1016/j.it.2012.10.00110.1016/j.it.2012.10.001 ↗
20. 10.1007/s00262-014-1549-410.1007/s00262-014-1549-4 ↗
21. 10.1038/nm119610.1038/nm1196 ↗
22. 10.1016/j.pharmthera.2018.12.00410.1016/j.pharmthera.2018.12.004 ↗
23. 10.1080/13543776.2018.144129010.1080/13543776.2018.1441290 ↗
24. 10.1186/s13045-018-0644-y10.1186/s13045-018-0644-y ↗
25. 10.1038/s41416-019-0664-610.1038/s41416-019-0664-6 ↗
26. 10.1186/s40425-018-0351-910.1186/s40425-018-0351-9 ↗
27. 10.1007/s10637-019-00787-310.1007/s10637-019-00787-3 ↗
28. 10.1038/ncomms1344310.1038/ncomms13443 ↗
29. 10.1002/advs.20210095010.1002/advs.202100950 ↗
30. 10.1002/adma.20140503610.1002/adma.201405036 ↗
31. 10.1021/acsnano.9b0832010.1021/acsnano.9b08320 ↗
32. 10.1002/adma.20190296010.1002/adma.201902960 ↗
33. Wang L. · Adv. Sci. · 2022 · 9 · e220406710.1002/advs.202204067 ↗
34. 10.1002/adma.20210218810.1002/adma.202102188 ↗
35. 10.1016/j.eururo.2003.11.01210.1016/j.eururo.2003.11.012 ↗
36. 10.1039/C9TB02271F10.1039/C9TB02271F ↗
37. 10.1021/acsami.1c2414810.1021/acsami.1c24148 ↗
38. 10.1021/acsami.9b0956810.1021/acsami.9b09568 ↗
39. 10.1021/acsnano.5b0808410.1021/acsnano.5b08084 ↗
40. 10.1021/nn900679710.1021/nn9006797 ↗
41. 10.1021/la300046w10.1021/la300046w ↗
42. 10.1021/jp200868210.1021/jp2008682 ↗